#NACFC2021 – Trikafta Aids Patients Who Cannot Use Other Modulators

#NACFC2021 – Trikafta Aids Patients Who Cannot Use Other Modulators

311436

#NACFC2021 – Trikafta Aids Patients Who Cannot Use Other Modulators

Treatment with Trikafta improves lung function in people with cystic fibrosis (CF) who are not eligible for treatment with other CFTR modulators, according to interim data from an observational study. Results were shared at this year’s North American Cystic Fibrosis Conference (NACFC) in the presentation, “Real-world clinical effectiveness of elexacaftor/tezacaftor/ivacaftor and ivacaftor in people with CF: Interim results from the HELIO study.” The study was supported by Vertex Pharmaceuticals, which markets Trikafta. CF is caused…

You must be logged in to read/download the full post.